Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan

References

• Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000;50(9):696–702. doi: 10.1046/j.1440-1827.2000.01108.x.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011(1):498–505. doi: 10.1182/asheducation-2011.1.498.
   PubMed Web of Science ®Google Scholar
• Japanese Society of Hematology. Zōketsukishuyō shinryō gaidorain [Practical guidelines for hematological malignancies]; 2018 [cited 2023 Mar 28]. Available from: http://www.jshem.or.jp/gui-hemali/table.html
   Google Scholar
• Iftikhar R, Mir MA, Moosajee M, et al. Diagnosis and management of diffuse large B-cell lymphoma: Society of Medical Oncology, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology joint clinical practice guideline. J Clin Oncol Glob Oncol. 2021;7:1647–1658. doi: 10.1200/GO.21.00320.
   Google Scholar
• Ngu H, Takiar R, Phillips T, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Am Soc Clin Oncol Educ Book. 2022;42(2):1–14. doi: 10.1200/JCO.19.00172.
   PubMedGoogle Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–363. doi: 10.1056/NEJMoa2115304.
   PubMed Web of Science ®Google Scholar
• Minds Manual Developing Committee, editor. Minds manual for guideline development 2020, ver. 3.0. Tokyo: Japan Council for Quality Health Care; 2021.
   Google Scholar
• NICE Decision Support Unit. TSD 19: Partitioned survival analysis as a decision modelling tool [cited 2023 Mar 29]. Available from: https://www.sheffield.ac.uk/nice-dsu/tsds/partitioned-survival-analysis
   Google Scholar
• Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health (C2H). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council [cited 2023 Mar 29]. Available from: https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf
   Google Scholar
• Jakobsen LH, Bøgsted M, Brown PN, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. J Clin Oncol. 2017;35(7):778–784. doi: 10.1200/JCO.2016.70.0765.
   PubMed Web of Science ®Google Scholar
• Shi Q, Schmitz N, Ou FS, et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol. 2018;36(25):2593–2602. doi: 10.1200/JCO.2018.77.9124.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822–1827. doi: 10.1093/annonc/mdy203.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. Abridged Life Table for Japan; 2021 [cited 2023 Mar 29]. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/life/life21/index.html
   Google Scholar
• Ohmachi K, Kinoshita T, Tobinai K, et al. A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Adv. 2021;5(4):984–993. doi: 10.1182/bloodadvances.2020002567.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s lymphoma classification project. J Clin Oncol. 1998;16(8):2780–2795. doi: 10.1200/JCO.1998.16.8.2780.
   PubMed Web of Science ®Google Scholar
• Tsutsué S, Makita S, Yi J, et al. Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma. Future Oncol. 2021;17(33):4511–4525. doi: 10.2217/fon-2021-0400.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Martelli M, Trněný M, et al. A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13(1):71. doi: 10.1186/s13045-020-00900-7.
   PubMed Web of Science ®Google Scholar
• NICE Decision Support Unit. TSD 14: Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data [updated 2013 Mar; cited 2023 Mar 29]. Available from: https://www.sheffield.ac.uk/media/34225/download?attachment
   Google Scholar
• Kane LT, Fang T, Galetta MS, et al. Propensity score matching: a statistical method. Clin Spine Surg. 2020;33(3):120–122. doi: 10.1097/BSD.0000000000000932.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma [published correction appears in. Blood. 2021;137(13):1844]. Blood. 2021;137(5):600–609. doi: 10.1182/blood.2020006578.
   PubMed Web of Science ®Google Scholar
• Swinburn P, Shingler S, Acaster S, et al. Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56(6):1839–1845. doi: 10.3109/10428194.2014.970542.
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–e203. doi: 10.1111/ajco.12477.
   PubMed Web of Science ®Google Scholar
• Yakka kounou hayami hyou 2022 [Japanese drug tariffs 2022]. Tokyo: Igakutushinsya Co., Ltd.; 2022.
   Google Scholar
• Shinryou tensuu hayami hyou 2022-nen 4-gatsu zohoban [Medical treatment fee point April 2022]. Tokyo: Igakutushinsya Co., Ltd.; 2022.
   Google Scholar
• Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31(17):2103–2109. doi: 10.1200/JCO.2012.46.5203.
   PubMed Web of Science ®Google Scholar
• Awano N, Izumo T, Inomata M, et al. Medical costs of Japanese lung cancer patients during end-of-life care. Jpn J Clin Oncol. 2021;51(5):769–777. doi: 10.1093/jjco/hyaa259.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Komoto S, Shiroiwa T, et al. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43–51. doi: 10.1016/j.jval.2019.10.005.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [cited 2023 Mar 29]. Available from https://www.nice.org.uk/guidance/gid-ta10785/documents/html-content-5
   Google Scholar
• Terui Y, Rai S, Izutsu K, et al. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2021;112(7):2845–2854. doi: 10.1111/cas.14937.
   PubMed Web of Science ®Google Scholar
• Kambhampati S, Saumoy M, Schneider Y, et al. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood. 2022;140(25):2697–2708. doi: 10.1182/blood.2022016624.
   PubMed Web of Science ®Google Scholar
• Putri S, Setiawan E, Saldi SRF, et al. Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. BMC Health Serv Res. 2022;22(1):553. doi: 10.1186/s12913-022-07956-w.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193–1202. doi: 10.1016/j.jval.2021.03.010.
   PubMed Web of Science ®Google Scholar
• Myers RM, Hill BT, Shaw BE, et al. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. Cancer. 2018;124(4):816–825. doi: 10.1002/cncr.31114.
   PubMed Web of Science ®Google Scholar